Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa

Merck Sharp + Dohme Corp.

Istituto Di Richerche Di Biologia Molecolare P. Angeletti S.p.a.

Sanofi-a Ventis Deutschland Gmbh

Msd Italia S.r.l.

Istituto Di Ricerche Di Biologia Molecolare P. Angletti Spa

Joerg Habermann

Frank Narjes

Uwe Koch

Ian Stansfield

Nigel J Liverton

Anandan Palani

Hao Wu

Peng Li

Casey Cameron McComas

Xing Dai

Shuwen He

Hong Liu

Richard Soll

Xuanjia Peng

Simona Ponzi

Maria Del Rosario Rico Ferreira

Qun Dang

Nicolas Zorn

Zhong Lai

Immacolata Conte

Stefania Colarusso

Ravi P Nargund

Gerhard Jaehne

Dong Xiao

Reinhard Kirsch

Michael Rowley

Hans Ulrich Stilz

Otmar Klingler

Clare London

Olaf Ritzeler

Christian Engel

Klaus-ulrich Weithmann

Bernhard Neises

Caterina Ercolani

Bernard Pirard

Angela Mackay

Elena Capito

Casey Cameron Mccomas

Nicholas Zorn

Qung Dang

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5B polymerase inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5B polymerase activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system. 

Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases

Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases

Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases

The present invention relates to pentacyclic indole derivatives of formula (I): wherein A, Ar, R, R, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. 

Pentacyclic indole derivatives as antiviral agents

Compounds of the formula (I) wherein A, B, D, M, Ar, W, X, Y, Z and Rare as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed. 

Antiviral indoles

A class of macrocyclic compounds of formula (I), wherein R, A, Ar, B, D, F, M, Q, Q, W, X, Y and Z are defined herein, that are useful as inhibitors of viral proteases, particularly the hepatitis C virus (HCV) NS3 protease, are provided. Also provided are processes for the synthesis and use of such macrocyclic compounds for treating or preventing HCV infection. 

Therapeutic compounds

The present invention relates to tetracyclic thienopyrrole compounds of formula (I), wherein Ar, A, D1, D2, W, X, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. 

Thienopyrroles as antiviral agents

The present invention relates to indole compounds of the formula (I): wherein R, R, R, R, A, E and X are as defined herein, and pharmaceutically acceptable salts thereof, useful in the prevention and treatment of hepatitis C infections. 

Indole derivatives as antiviral agents

Compounds of the formula (I): wherein A, B, D, M, Ar, W, X, Y, Z and Rare as defined herein, are useful in the prevention and treatment of hepatitis C infections. The compounds, their preparation, pharmaceutical compositions containing them and their use in medicine are disclosed.

The present invention relates to tetracyclic indole compounds of formula (I); wherein R, R, R, R, A, Ar, Y and Z are defined herein, and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising them, and their use for the treatment or prevention of infection by hepatitis C virus. 

Tetracyclic indole derivatives as antiviral agents

Compounds of the formula I are suitable for preparing pharmaceuticals for the prophylaxis and therapy of disorders in whose course an increased activity of NF&#x3ba;B is involved.

Substituted indoles

Pyrimidine-4,6-dicarboxylic acid diamides of the formula I are suitable for selectively inhibiting collagenase (MMP 13). The pyrimidine-4,6-dicarboxylic acid diamides can therefore be used for treating degenerative joint diseases.

Pyrimidine-4,6-dicarboxylic acid diamides for selectively inhibiting collagenases

Growing community of inventors

Rome, Italy

Joerg Habermann